Burns Pipeline Assessment, 2023 | In-depth Insights Into the Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Emerging Therapies, and Treatment Algorithm | Key Companies - MediWound (NexoBrid (anacaulase-bcdb)), Alexis

Globally, about 12+ key pharma and biotech companies are working on 12+ pipeline drugs in the Burns therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Burns are the most distressing forms of injury, causing extensive pain and damage to the skin. They are considered one of the leading causes of death worldwide. Everyday 30,000 people are affected by burns, which accounts for over 11 million people globally every year. Inadequate access to timely, safe, and efficient care continues to be a major global health concern. In the current market scenario, the standard treatment for skin burns involves medications, wound dressings, therapy, and surgery. The treatment goals are to control pain, remove dead tissue, prevent infection, reduce scarring risk, and regain function. The treatment depends on the severity of the burn.

As per DelveInsight's assessment, the Burn therapeutics market is anticipated to change in the coming years owing to the improvement in the treatment, incremental healthcare spending across the world, and the expected launch of emerging therapies. Companies like CUTISS AG, RenovaCare, Mallinckrodt Pharmaceuticals, and others across the globe are working toward developing more advanced treatment therapies for skin burns.

"Burns Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Burns Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Burns Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Burns Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Burns treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Burns market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More About the Emerging Therapies and Evolving Treatment Algorithms:
https://www.delveinsight.com/report-store/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Burns Pipeline Drugs Route of Administration (ROA)
Products have been Categorized Under Various ROAs, such as:
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical

Molecule Type
Products have been categorized under various molecule types, such as:
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy

Burns Emerging Drug's Mechanism of Action (MOA):
- Peptide hydrolase inhibitors
- Collagen type VII replacements
- Protein-lysine 6-oxidase inhibitors
- Platelet-derived growth factor modulators
- Connexin 43 inhibitors

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Burns Therapeutics Analysis
There are approx. 12+ key companies developing the therapies for Burns. Currently, NeoMatrix Therapeutics is leading the therapeutics market with Burns drug candidates in the most advanced stage of clinical development among all the key players present in the market.

The Leading Companies in the Burns Therapeutic Market Include:
- NeoMatrix Therapeutics
- Amniotics
- Alloksys Life Sciences
- Medline Industries
- Skingenix, Inc.
- Anterogen
- Noveome Biotherapeutics
- Phagelux Inc.
- Bioharmony Therapeutics
- Amarantus Bioscience
And Many Others

Burns Drugs Covered in the Report Include:
- NMT- cP12: NeoMatrix Therapeutics
- MW-III: Skingenix
- EHSG-KF (denovoSkin): CUTISS AG
- NMT-cNP8: NeoMatrix Therapeutics, Inc.
- TOP-N44: Topadur
- AGLE-102: Aegle Therapeutics
- PXS-6302: Pharmaxis Ltd
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Burns Current Treatment Patterns
4. Burns - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Burns Late-Stage Products (Phase-III)
7. Burns Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Burns Discontinued Products
13. Burns Product Profiles
14. Burns Key Companies
15. Burns Key Products
16. Dormant and Discontinued Products
17. Burns Unmet Needs
18. Burns Future Perspectives
19. Burns Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.